financetom
Business
financetom
/
Business
/
CNN must face Project Veritas' defamation lawsuit, US appeals court rules
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
CNN must face Project Veritas' defamation lawsuit, US appeals court rules
Nov 9, 2024 12:27 PM

Nov 7 (Reuters) - A federal appeals court on Thursday

revived a defamation lawsuit accusing CNN of defaming Project

Veritas in its explanation of why the conservative group, which

is often accused of using deceptive tactics, was suspended from

Twitter in 2021.

The 11th U.S. Circuit Court of Appeals in Atlanta said

Project Veritas plausibly alleged a defamation claim under

applicable New York law after CNN host Ana Cabrera suggested on

air that the Twitter ban was for "promoting disinformation."

It also said Project Veritas plausibly alleged that CNN

acted with actual malice, meaning it knew its statements about

the group were false or acted with reckless disregard for the

truth.

CNN and its lawyers did not immediately respond to requests

for comment. Project Veritas' lawyers did not immediately

respond to similar requests.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
ConocoPhillips-Marathon Merger Hits Hurdle: FTC Requests More Info, Delays Deal
ConocoPhillips-Marathon Merger Hits Hurdle: FTC Requests More Info, Delays Deal
Jul 12, 2024
On Thursday, ConocoPhillips ( COP ) and Marathon Oil Corporation ( MRO ) received a Second Request from the Federal Trade Commission (FTC) to extend the Hart-Scott-Rodino waiting period. The merger will proceed after the FTC review and fulfillment of other conditions in the merger agreement. ConocoPhillips ( COP ) and Marathon are working with the FTC on its review...
Biogen, Eisai Get Approval for Leqembi in Israel for Treatment of Alzheimer's Disease
Biogen, Eisai Get Approval for Leqembi in Israel for Treatment of Alzheimer's Disease
Jul 12, 2024
10:48 AM EDT, 07/12/2024 (MT Newswires) -- Biogen (BIIB) and Eisai said Friday that the Leqembi has been approved in Israel for the treatment of patients with Alzheimer's disease. The drug should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, according to the joint statement. Leqembi's approval is based on results from the phase...
Wells Fargo Second-Quarter Net Interest Income Misses Expectations; Stock Falls Intraday
Wells Fargo Second-Quarter Net Interest Income Misses Expectations; Stock Falls Intraday
Jul 12, 2024
10:54 AM EDT, 07/12/2024 (MT Newswires) -- Wells Fargo ( WFC ) results rose above market expectations for the second quarter, but the lender's net interest income declined annually and fell short of analysts' estimates. Earnings increased to $1.33 a share for the quarter through June 30 from $1.25 a year earlier, the banking giant said Friday, compared with the...
Strathcona Resources Rating Affirmed, Withdrawn by Fitch
Strathcona Resources Rating Affirmed, Withdrawn by Fitch
Jul 12, 2024
11:00 AM EDT, 07/12/2024 (MT Newswires) -- Fitch Ratings on Friday said it affirmed Strathcona Resources' ( STHRF ) long-term issuer default rating at B+ with a stable outlook. Also, the rating agency affirmed the company's first lien-secured revolving credit facility at BB+/RR1 and upgraded the senior unsecured bond to B+/RR4 from B/RR5. After these actions, Fitch withdrew the issuer...
Copyright 2023-2026 - www.financetom.com All Rights Reserved